Reference Detail

Ref Type
PMID
Authors Y. Kuboki, N. Matsubara, H. Bando, K. Shitara, K. Yoh, T. Kojima, I. Ohno, H. Takahashi, K. Harano, S. Kondo, H. Hirai, C. Morizane, T. Doi
Title First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors
Journal Ann Oncol
Vol
Issue
Date
URL http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
Abstract Text Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
TAS-120 TAS-120 27 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
TAS-120 FGFR Inhibitor (Pan) 18 TAS-120 is a third-generation pan-FGFR inhibitor, which result in the inhibition of FGFR-mediated signal transduction pathways and tumor cell proliferation (PMID: 31109923).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 amp stomach cancer predicted - sensitive TAS-120 Phase I Actionable In a Phase I trial, TAS-120 treatment resulted in clinical response in a gastric cancer patient harboring FGFR2 amplification (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). detail...
Unknown unknown urinary bladder cancer not applicable TAS-120 Phase I Actionable In a Phase I trial, TAS-120 treatment resulted in stable disease over 24 weeks in a bladder cancer patient (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). detail...
Unknown unknown esophageal cancer not applicable TAS-120 Phase I Actionable In a Phase I trial, TAS-120 treatment resulted in clinical response in an esophageal cancer patient (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). detail...
FGFR2 fusion biliary tract cancer predicted - sensitive TAS-120 Phase I Actionable In a Phase I trial, TAS-120 treatment resulted in stable disease over 24 weeks in two biliary tract cancer patients harboring FGFR2 fusions (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). detail...
Unknown unknown Advanced Solid Tumor not applicable TAS-120 Phase I Actionable In a Phase I trial, TAS-120 treatment resulted in clinical response in 5.5% (2/36) and stable disease over 24 weeks in 5.5% (2/36) of patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). detail...